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ORIGINAL ARTICLE

Gutting the brain of inflammation: A key role of gut
microbiome in human umbilical cord blood plasma therapy in
Parkinson's disease model
Jea‐Young Lee1,2 | Julian P. Tuazon1,2 | Jared Ehrhart3 | Paul R. Sanberg1,2,4,5 |
Cesario V. Borlongan1,2
1

Center of Excellence for Aging and Brain
Repair, Morsani College of Medicine,
University of South Florida, Tampa, Florida

2

Abstract
Current therapies for Parkinson's disease (PD), including L‐3,4‐dihydroxyphenylala‐
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erated mixed results with the eventual induction of dyskinetic side effects. Although
capacity of differentiation into mature dopaminergic neurons, their transplantation sig‐
nificantly attenuates parkinsonian symptoms likely via bystander effects, specifically
stem cell graft‐mediated secretion of growth factors, anti‐inflammatory cytokines,
or synaptic function altogether promoting brain repair. Recognizing this non‐cell re‐
placement mechanism, we examined here the effects of intravenously transplanted
combination of hUCB‐derived plasma into the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydro‐
pyridine (MPTP)‐induced rat model of PD. Animals received repeated dosing of either
hUCB‐derived plasma or vehicle at 3, 5 and 10 days after induction into MPTP lesion,
then behaviourally and immunohistochemically evaluated over 56 days post‐lesion.
Compared to vehicle treatment, transplantation with hUCB‐derived plasma signifi‐
cantly improved motor function, gut motility and dopaminergic neuronal survival in
the substantia nigra pars compacta (SNpc), which coincided with reduced pro‐inflam‐
matory cytokines in both the SNpc and the intestinal mucosa and dampened inflamma‐
tion‐associated gut microbiota. These novel data directly implicate a key pathological
crosstalk between gut and brain ushering a new avenue of therapeutically targeting
the gut microbiome with hUCB‐derived stem cells and plasma for PD.
KEYWORDS

cord blood, gut microbiome, neurodegeneration, neuroinflammation, plasma

1 | I NTRO D U C TI O N

cell loss in the substantia nigra (SNpc) leading to a deficiency of
dopamine in the striatum, and formation of intracellular inclusions,

Parkinson's disease (PD) ranks as the second‐most prevalent neu‐
1

called Lewy bodies, which contain α‐synuclein aggregates. 2 The

rodegenerative disorder which affects the aging population. The

clinical symptoms of PD have been routinely defined as progres‐

major neuropathological hallmarks of PD consist of dopaminergic

sive motor abnormalities, which include tremors, muscle rigidity,

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine
5466

|

wileyonlinelibrary.com/journal/jcmm
	

J Cell Mol Med. 2019;23:5466–5474.

|

LEE et al.

5467

bradykinesia, impaired balance and freezing of gait.1 However, PD

intravenous (iv) delivery of CBP could provide therapeutic benefit in

is also associated with many non‐motor symptoms, such as cogni‐

both gut and brain tissues. This would provide valuable translational

tive impairment, and abnormalities in the function of the gut, which

guidance for the development of a stand‐alone CBP therapeutic or

contribute to overall morbidity of the disease.1,3 Unfortunately, de‐

quite possibly a combined CBP with stem cell therapy in targeting

spite the scientific advances in our knowledge of disease pathology,

the gut microbiome for PD treatment.

there is no cure for PD, only relief from its symptoms. Current thera‐

The aim of this study was to determine if CBP alone is beneficial

peutic applications to treat PD target pharmacological replacement

in reducing PD‐associated pathology in the brain and gut induced by

of striatal dopamine (ie, Levodopa), coupled with non‐dopami‐

intraperitoneal (ip) administration of an MPTP insult. Since the full

nergic drugs to attenuate both motor and non‐motor symptoms.

efficacy of a CBP‐based therapy might not be ascertainable using

Additionally, deep brain stimulation has also been shown to provide

a single injection, multiple administrations of CBP were provided

therapeutic relief of symptoms.1,3 Interestingly, an enriched envi‐

over a 14 day period. To assess the efficacy of this treatment plan

ronment has also exhibited potential for reducing oxidative damage

the motor, neurological and non‐motor related pathologies of PD

and olfactory dysfunction in PD mice.4 Studies in stem cell‐based

assessed at baseline (day 0) and at days 1, 3, 7 and 14 after MPTP

regenerative medicine, which also attempt to exogenously replace

administration. Tissue pathology was examined using immunohisto‐

dopamine or stimulate endogenous host brain repair, 5,6 represents

chemistry to help determine the extent of the MPTP‐induced nigral

efforts towards disease‐modifying outcomes as well.

lesion and resultant inflammation in both the brain and intestinal tis‐

Cord blood plasma (CBP), which can be readily obtained from

sues. Finally the populations of several inflammatory gut‐related mi‐

human umbilical cord blood (hUCB) during routine cell isolation,

crobiota were assayed to determine the relative inflammatory state

has mainly been considered a waste product. The potential trophic

of the gut microbiome. These study results provide insight into the

effects provided by CBP have been shown through culture sup‐

potential of a CBP therapy for the treatment of neurodegenerative

plementation of hUCB‐derived mesenchymal stem cells (MSCs),7

diseases.

8

9

hUCB‐derived T‐lymphocytes, human dental cells or human endo‐
thelial colony‐forming cells10 in vitro. Indeed, CBP may have under‐
lying potential as a source of treatment for neurological diseases,
given that hUCB cell grafts migrate to injury sites11 and emit growth
factors that ameliorate ischaemia,12 hUCB mononuclear cells in‐

2 | M ATE R I A L S A N D M E TH O DS
2.1 | hUCB plasma

crease neurogenesis in aged rats,13 and neural cells derived from

Frozen units of hUCB plasma (CBP) were provided by Saneron

human placentas attenuate neuroinflammation and confer neuro‐

CCEL Therapeutics, Inc The CBP was aseptically isolated using the

protection in PD rats.14 Additionally, in vivo studies determining

Sepax 2 fully automated cell processing system (Biosafe America

the therapeutic potential of CBP in rats modelling acute ischemic

Inc, Houston, TX), and tested for sterility using the BacT/ALERT

stroke have been investigated with results showing enhancement

microbial detection system (bioMérieux, Durham, NC) prior to

of neurogenesis and reduced inflammation providing significant

freezing.

functional recovery post‐stroke.15 Moreover, α‐secretase extracted
from CBP has also demonstrated the ability to improve cognitive
deficits and amyloid plaque formation in Alzheimer's disease mouse

2.2 | Animals

models.16 Several studies have also investigated the composition

All experimental procedures were approved by the University of South

of CBP with reports finding high amounts of various growth fac‐

Florida Institutional Animal Care and Use Committee (IACUC). Male

tors, along with a unique cytokine profile consisting of a low con‐

Sprague‐Dawley rats (8 weeks old, n = 30) were housed under nor‐

centration of various pro‐inflammatory cytokines. 8,17,18 Although

mal conditions (20°C, 50% relative humidity, and a 12‐hour light/dark

CBP can have beneficial effects on cells in culture, the ability of

cycle). All necessary precautions were taken to reduce pain and suf‐

CBP to elicit therapeutic benefits in models of neurodegenerative

fering of animals throughout the study. Animals were closely checked

disorders must be determined before developing clinically relevant

daily throughout the 2 week study period. All studies were performed

CBP‐based therapies.

by personnel blinded to the treatment condition.

Since inflammation has been connected to the progressive ex‐
acerbation of neurological diseases

19

and the inflammatory gut

microbiome has recently been linked to a number of neurological

2.3 | Preparation of the animal model

disorders, 20-24 including Parkinson's, 25-27 this study was designed

To induce degeneration of nigrostriatal dopaminergic neurons in 8‐

to analyse the gut for MPTP‐induced PD‐related dysfunction and

week‐old male Sprague‐Dawley rats, 100 µL of MPTP (20 mg/kg;

to determine the therapeutic potential CBP at reducing the gut in‐

Sigma Aldrich, St. Louis, MO) was intraperitoneally (ip) injected every

flammation that may be present in this particular model. Findings

2 hours for a total of three injections per animal in both vehicle (n = 10)

from this study may aid in providing further support to the notion

and CBP (n = 10) groups; sham animals (n = 10) received 0.9% saline

that a non‐dopaminergic and non‐CNS organ may contribute to PD

(100 µL). All surgical procedures were performed under sterile condi‐

pathology. 21,23,28 Additionally it is of specific interest to determine if

tions. On days 3, 5 and 10 post‐lesion, the plasma group received CBP

5468
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F I G U R E 1 Schematic representation of experimental design. Animals received 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)
insult at day 0, and injections of cord blood plasma on days 3, 5 and 10 post insult. Animals underwent behavioural testing to document
neurological and motor deficits at days 7 and 14 post MPTP induction of Parkinsonian pathology

(500 µL) iv with the sham and vehicle groups both receiving PBS iv
(500 µL; Figure 1). Animal weight was recorded at the onset of the

2.6 | Gastric emptying

study, and monitored over the next three consecutive days post‐

At the study termination day, all groups were provided an oral solu‐

MPTP insult.

tion of charcoal (10%) in acacia gum (2%) by gavage. Animals were
returned to their home cages for 30 minutes following oral adminis‐

2.4 | Behavioural testing

tration, then euthanized by carbon dioxide inhalation. The intestines
were then exteriorized and the distance traveled by the charcoal

Behavioural tests for the observation of parkinsonian‐like motor and

meal was measured, in addition to the full length of the intestines

non‐motor deficits were administered at intervals prior to, 7 days

(from the pylorus through the anus). Results are expressed as dis‐

post and 14 days post MPTP lesion. Standard behavioural testing

tance traveled in centimeters as well as percent of distance traveled

included rotarod, forelimb akinesia and paw grasp were performed

relative to the full length of the intestines.

to observe generation of the classical motor‐function deficits and
neurological dysfunction seen in PD. Distal colonic propulsion and
gastric emptying studies (described below) were performed to ob‐
serve changes in the gut associated non‐motor symptoms of PD.

2.7 | Tissue collection
Under deep anesthesia, the rats were sacrificed at 14 days after
MPTP insult. Animals were perfused transcardially with approxi‐

2.5 | Distal colonic propulsion

mately 200 mL of ice cold PBS followed by 200 mL of 4% paraform‐
aldehyde in PBS. The intestines and brains of these animals were

To measure colonic propulsion on day 7 and day 14 after MPTP

removed and post‐fixed in the same fixative for 24 hours at 4°C.

administration, a single 5‐mm‐diameter glass bead was inserted

These tissues were then transferred to 30% sucrose in PB for at

into the distal colon to a distance of about 2 cm from the anus of

least 16 hours prior to tissue sectioning. Coronal sections were cut

each rat. After bead insertion, the rats were replaced individu‐

(40 µm) using a cryostat, collected and stored in a cryoprotectant

ally without food and water in their home cages. Thereafter the

solution at −20°C.

animals underwent observation to ensure they showed normal
behaviour, and the amount of time necessary for excretion of the
glass bead was measured. The time required for expulsion of the

2.8 | Immunohistochemistry

glass bead, called mean expulsion time (MET), was determined

Staining tyrosine hydroxylase (TH) conducted on every sixth

(to the nearest 1.0 second) for each rat and the inhibition of co‐

coronal section throughout the entire substantia nigra (SN). In

lonic propulsion measured as the increase in MET versus control

all animals, sections were anatomically matched. Eight free‐float‐

rats. The higher the MET value, the stronger the inhibition of

ing coronal sections from each rat were washed three times in

colonic propulsion.

0.1 M PBS to remove traces of the cryoprotectant. Afterwards,

|
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all sections were incubated in a 0.3% hydrogen peroxide (H2O2)
solution for 20 minutes, then washed with PBS three times at

5469

2.10 | Gut microbiome analysis

10 minutes each. Next, all sections were incubated for 1 hour in

The presence and concentration of specific inflammatory, po‐

a blocking solution composed PBS supplemented with 3% nor‐

tentially harmful, microbiotic species residing within the gut

mal goat serum and 0.2% Triton X‐100. Sections were then incu‐

was determined. Fluorescent in‐situ hybridization (FISH) analy‐

bated overnight at 4°C with rabbit anti‐rat TH (1:100 TH, AB152;

sis was used to identify the specific microbiota within the feces

Millipore, Burlington, MA) antibody diluted in PBS supplemented

of the rats in this study. Fecal matter (1 g) collected during

with 3% normal goat serum and 0.1% triton X‐100. Sections were

tissue processing was suspended in 2 mL of PBS and homog‐

then washed three times with PBS and incubated for 1 hour in

enized by repeated pipetting with a 1mL micropipettor and

biotinylated goat anti‐rabbit secondary antibody (1:300; Vector

mixed using a vortex. Four per cent paraformaldehyde (6 mL)

Laboratories, Burlingame, CA) diluted in PBS supplemented with

was added to the homogenized feces and stored overnight at

normal goat serum, and 0.1% Triton X‐100. Next, the sections

4°C. The tubes were then centrifuged at 10 g for 5 minutes to

were incubated for 60 minutes in avidin‐biotin substrate (ABC kit;

sediment undigested material. The bacterial laden superna‐

Vector Laboratories) and washed with PBS three times at 10 min‐

tant was transferred a new tube and the centrifugation step

utes each wash. All sections were then incubated for 1 minute in

was repeated. Following the final centrifugation the superna‐

3, 30‐diaminobenzidine (DAB) solution (Vector Laboratories) and

tant was transferred to a new tube and centrifuged at 60 g for

washed three times with PBS for 10 minutes each wash. Sections

5 minutes to pellet any bacteria present. The supernatant was

were then mounted onto glass slides, set to dry for 24 hours and

discarded and the pellet was resuspended in 500 µL of hybridi‐

dehydrated with increasing concentrations of ethanol (70%, 95%

zation solution comprised of 50% (v/v) formamide, 100 µg/mL

and 100%) for 2 minutes each and one time in xylenes for 2 min‐

salmon sperm DNA, 5× saline‐sodium citrate buffer, and 0.1%

utes. The slides were then cover‐slipped using Permount mounting

(v/v) Tween 20. After a 30 minutes incubation at 37°C, 50 µL

medium (Fisher Scientific, Pittsburg, PA). Control studies included

volumes of each sample were combined with 2.7 µL of fluores‐

exclusion of primary antibodies substituted with 3% normal

cently labelled oligonucleotides in a new tube and incubated

goat serum in PBS. No immunoreactivity was observed in these

in the dark for 2.5 hours at 45°C. The tubes were then cen‐

controls.

trifuged at 60 g for 5 minutes, the supernatant discarded, and
the pellet was washed by resuspending in 20 µL of 0.1 SSC.

2.9 | Immunofluorescence

This wash step was repeated an additional two times. After the
final wash, the samples were resuspended in 20 µL of PBS, and

Immunofluorescent staining for the inflammatory markers of major

centrifuged at 13 000g for 5 minutes. Transfer 10 µL to a new

histocompatibility complex (MHCII) and tumor necrosis factor alpha

slide that has been cleaned with ethanol (EtOH) and add 5 µL

(TNF‐α) were conducted on every sixth coronal section throughout

of vectashield mounting medium with 2‐(4‐Amidinophenyl)‐6‐

the entire SN. In all animals, sections were anatomically matched.

indolecarbamidine dihydrochloride, 4′,6‐Diamidino‐2‐phenylin‐

Eight free‐floating coronal sections (40 mm) from each rat were

dole (DAPI). The slides were carefully cover‐slipped and images

washed three times in 0.1 M PBS to remove traces of the cryo‐

were collected at 40× using an Olympus FV1000 laser scanning

protectant. The sections were then incubated in blocking solution

confocal microscope equipped with Fluoview SV1000 imaging

for 1 hour using PBS supplemented with 10% normal horse serum

software.

and 0.1% Triton X‐100. Sections were then incubated overnight at
4°C with mouse anti‐rat MHC II (anti‐RT1B (OX‐6); NB100‐65541;
Novus Biologicals, Centennial, CO) or rabbit anti‐rat TNF‐α

2.11 | Statistical analysis

(ab6671; Abcam, Cambridge, MA) antibodies in PBS supplemented

Behavioural data, image analyses and microbiome data are presented

with 10% normal horse serum and 0.1% triton X‐100. Sections were

as mean ± SD Statistical analysis was performed using Statview

washed three times for 10 minutes in PBS and then incubated in

(Abacus Corporation). The results for the assays in this study were

PBS supplemented with 10% normal horse goat serum and 0.1%

analysed using one‐way ANOVA with Bonferroni post‐hoc analysis.

Triton X‐100 containing corresponding secondary antibodies,

A value of P < 0.05 was considered significant.

goat anti‐rabbit IgG‐Alexa 488 (green; 1:500; Invitrogen) and goat
anti‐ mouse IgG‐Alexa 594 (red; 1:750; Invitrogen), for 90 minutes.
Finally, sections were washed five times for 10 minutes in PBS, and
cover‐slipped with Fluoromount (Sigma; F4680). Sections were ana‐
lyzed in independent channels with an Olympus FV1000 laser scan‐
ning confocal microscope equipped with Fluoview SV1000 imaging
software. Control studies included exclusion of primary antibodies
substituted with 3% normal horse serum in PBS. No immunoreac‐
tivity was observed in these controls.

3 | R E S U LT S
3.1 | Effects of CBP on motor, neurological and
gastrointestinal function in PD animals
The efficacy of multiple injections CBP was investigated in a gut‐in‐
duced MPTP rat model of PD. As no adverse reactions were observed
in any of the animals receiving iv administration of CBP all animals

5470
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F I G U R E 2 Effect of cord blood plasma on motor, neurological and gastrointestinal function in Parkinson's disease (PD) animals. The
motor and non‐motor related Parkinsonian pathologies were observed in a gut‐induced 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
(MPTP) rat model of PD. Initially, rotarod testing did not show much benefit at 7‐d post‐transplant (A), while significant improvements in
motor function were observed at the 14‐d time point (B). Additionally, significant improvements non‐motor PD dysfunction were observed
in both time points for colonic motility (C,D) and the end‐of‐study charcoal meal gastrointestinal transits test (F) in MPTP lesioned rats that
received CBP treatment. *,&: P < 0.05, **: P < 0.01

remained in the study until completion. Results showed that animals

amount of time needed to expel the bead. Testing at day 7 showed a

which received CBP after the MPTP insult displayed a potential im‐

slight decrease in the average time necessary for bead expulsion in an‐

provement in motor function as revealed by rotarod test compared

imals that received CBP vs vehicle controls (Figure 2C), with significant

to the vehicle group at 7 day time point (Figure 2A), with this effect

(P < 0.01) reductions observed at both the 7 and 14 day time points

reaching significance (P < 0.01) by the 14 day time point (Figure 2B).

(Figure 2D). Additionally, GI transit was observed by providing ani‐

Additional observations of neurological function consisting of forelimb

mals with a charcoal meal, by gavage, approximately 30 minutes prior

akinesia did show the generation of PD‐like neurological dysfunction,

to euthanasia. During tissue collection the distance the charcoal meal

but did not show any notable improvements by the end of the study

traveled within the intestines was measured (Figure 2E). A significant

(data not shown). Paw grasp testing to determine the extent of motor

(P < 0.01) restoration in GI transit of the charcoal meal was observed in

function deficits in this gut‐MPTP model of PD showed a strong trend

animals that received CBP vs vehicle controls (Figure 2F).

towards significance starting around the time of the second CBP ad‐
ministration and continued to the 14 day time point (data not shown).
To determine the efficacy of CBP to reduce the parkinsonian re‐
lated changes to the gastrointestinal (GI) system, colonic motility and

3.2 | Effects of CBP on the histopathology of PD
brain and gut

GI transit tests were performed. Colonic motility was observed by in‐

Histopathological staining of brain tissues was performed to document

serting a small glass bead into the animal's rectum and measuring the

changes in dopaminergic neuron populations in the SNpc. Additionally,

|
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immunofluorescence identifying immune cell activation, and TNF‐α

SNpc was significantly (P < 0.01) reduced in response to CBP treat‐

expression in both the brain and gut tissue was performed. Staining

ment (Figure 3C), with the staining for TNF‐α also showing significant

for the enzyme TH, a marker of dopaminergic neurons, revealed a re‐

(P < 0.01) reductions in the expression of this pro‐inflammatory cy‐

duction in the extent of dopaminergic neuron cell loss in animals given

tokine in MPTP lesioned animals that received CBP vs vehicle controls

CBP vs vehicle controls (Figure 3A). Image analysis of this TH staining

(Figure 2D). These effects were mirrored in the gut tissue of these ani‐

revealed that animals that received CBP vs vehicle controls showed a

mals with a significant (P < 0.01) reduction of both MHCII positive im‐

significant (P < 0.01) reduction in dopaminergic depletion (Figure 3B).

mune cells and TNF‐α cytokine production in animals treated with CBP

Additionally, the presence of immune cells populations (MHCII) in the

vs vehicle controls (Figure 3E and 3, respectively).

F I G U R E 3 Effect of cord blood plasma (CBP) on the histopathology of Parkinson's in the brain and gut. On day 14 following induction
of Parkinson's disease pathology with intraperitoneal injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) the therapeutic
effect of CBP treatment was observed in brain and gut tissues. MPTP lesioned rats treated with CBP noted significant reduction in TH‐
cell depletion in the substantia nigra (A,B) paired with a significantly decreased inflammatory response as evidenced by decreased major
histocompatibility complex (MHCII) and tumour necrosis factor alpha (TNF‐α) intensity in the brain of CBP‐treated animals (C,D). Similarly,
the inflammation of the gut found to be significantly reduced through decreased MHCII (E,F) and TNF‐α (G,H) intensity present in the
intestinal villi of animals treated with CBP. These findings parallel the trend of behavioural improvements in these animals that received
intravascular injections of plasma. *,&: P < 0.05, **: P < 0.01 Scale bar in A is 50 µm. Scale bar in C, E, G is 100 µm

5472
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F I G U R E 4 Effect of cord blood plasma (CBP) on populations of inflammatory microbiota. In tandem with the behavioural and histological
assays, we also assayed the gut for three biomes associated with inflammation. The levels of (A) LAB158, (B) BAC303 and (C) EREC482
were detected using a fluorescent in‐situ hybridization assay, and found to be elevated at day 14 following 1‐methyl‐4‐phenyl‐1,2,3,6‐
tetrahydropyridine (MPTP) lesion in lesioned animals treated with vehicle. These levels were reduced in lesioned animals that received CBP,
with significant reductions found for both LAB158 and BAC303, suggesting that the plasma exerted anti‐inflammatory effects in the gut
that may have contributed to the observed functional recovery. *,&: P < 0.05
In the development of treatments for PD, dopaminergic cell re‐

3.3 | Effects of CBP on populations of inflammatory
microbiota in PD animals

placement has been widely considered as the most straightforward

The prevalence of several potentially harmful microbiota species were

paminergic cells into PD patients resulted in not only survival of the

investigated using FISH. While the levels of LAB158, BAC303, and

transplant but also integration into the host dopaminergic network.29,30

EREC482 were found to be elevated at day 14 following MPTP lesion

Unfortunately only modest improvements were observed with de‐

in lesioned animals treated with vehicle. Significant (P < 0.05) reduc‐

creasing positive effects seen over the long‐term in transplanted PD

tions in the amount of LAB158 and BAC 303 were observed in the gut

patients.31,32 Additionally, a small group of patients that received fetal

of MPTP animals that were given multiple injections of CBP vs vehi‐

dopaminergic transplants displayed worsening dyskensias.33 While

cle control (Figure 4A, 4). While the population of EREC482 also de‐

the strategy of conventional dopaminergic cell replacement is still

creased in response to CBP treatment this observation was not found

being pursued,34 other effects relating simply to the transplantation

to carry significance (Figure 4C).

of stem cells appears to produce therapeutic benefit both peripherally

and appealing approach. The first transplantation of fetal derived do‐

and centrally. These secondary effects, previously examined in animal

4 | D I S CU S S I O N

models of PD,35,36 seems to be primarily attributable to alterations
in the gut microbiome that reduce inflammation. This in turn may re‐
duce dopaminergic cell loss and promote amelioration of parkinsonian

In this study, the potential of CBP as a viable therapeutic agent for both

symptoms. The anti‐inflammatory properties of CBP observed in this

motor and non‐motor symptoms in the gut‐induced MPTP rat model of

study produce similar by‐stander effects, which reduce some gut re‐

PD was evaluated. Tests of motor function, neurological behaviour and

lated non‐motor PD deficits. Extending the study over a longer time

gastric motility were employed to investigate the therapeutic efficacy

period with higher doses of CBP may allow for the enhancement of

of CBP. The ability of CBP to reduce nigral dopaminergic cell loss, while

these by‐stander effects which may aid in preventing dopaminergic

preventing both immune cell activation and pro‐inflammatory cytokine

cell loss and allow for restoration of neurological function.

production was also determined. The effect of CBP on the elevated lev‐

While CBP shows promise as a potential therapeutic to treat the

els of inflammation‐associated microbiota in the gut was examined and

inflammatory gut observed in PD, the combination of CBP with cord

compared to levels observed in the vehicle group. The major study find‐

blood stem cells could be the next step in developing a novel PD

ings were that treatment with CBP: (a) significantly improved motor (ro‐

treatment. Previous studies have already shown that cord blood stem

tarod) and non‐motor (colonic motility; GI transit) function in PD animal;

cells are not only effective at extending the lifespan of PD animals,37

(b) significantly reduced the amount of dopaminergic (TH) cell loss in the

they also aid in retention of dopaminergic cells within the substantia

SNpc; (c) significantly reduced activation of immune cells (MHCII) and

nigra.38 Additionally, CBP has been shown to be an effective sup‐

reduced expression of TNF‐α in both brain and gut tissues; and (d) sig‐

plement in human primary cell cultures.7-10 Substitution of standard

nificantly decreased populations of inflammatory gut microbiota. To our

cord blood stem cell transplant diluents with CBP might provide a

knowledge, this is the first study investigating the potential for CBP to

more supportive microenvironment that enhances stem cell survival

be used therapeutically for the reduction of PD‐related gut pathology.

and increases the therapeutic efficacy of the transplanted cells.

|
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This study offers many novel observations that should lay the

physiological indices such as body weight and food consumption may

foundation for future mechanism and optimization studies of CBP.

be essential in validating these GI effects. Optimization of CBP timing

First, the findings show that cell‐free CBP was effective in attenu‐

of treatment, doses and routes of delivery as stand alone or in com‐

ating PD symptoms circumvents a major logistical hurdle of gener‐

bination with cord blood stem cells may provide the most effective

ating dopaminergic cells when contemplating large clinical trials of

and safe cell‐based regenerative medicine necessary to sequester the

cell transplantation. A basic translational gating item in the use of

inflammation‐plagued brain degeneration and gut microbiome that

stem cells for PD is the perceived requirement to generate ample

plagues PD and various neurodegenerative diseases.

supply of neural stem cells with dopaminergic phenotype. Thus,
the present observation that CBP may afford robust functional
recovery in PD circumvents the logistic requirement of generat‐

AC K N OW L E D G E M E N T S

ing stem cells and differentiating them into dopaminergic cells.
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Center of Excellence for Aging and Brain Repair, Department of

the most part limited to the brain, yet accumulating evidence has
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implicated a pathological crosstalk between the degeneration of
non‐dopaminergic and the dopaminergic system in mediating PD
non‐motor symptoms. 39-42 Indeed, a paradigm‐shifting hypothesis
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has been put forward that dopamine segregation in the striatum 43
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and likely the substantia nigra as well, may not fully capture the
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synaptic plasticity dysfunctions in PD. The propagation of neu‐

Therapeutics, Inc. PRS and CVB have patents for the application of

rodegeneration beyond the nigrostriatal dopamine pathway may

hUCB as a cell therapy for several disorders.

suggest a new venue for PD pathology and its treatment. Since
the gut microbiome has recently been linked to a number of neu‐
rological disorders, our study implicates the gut microbiome as an
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appealing target for CBP, as well as stem cell fate and cytokine

JYL, JPT, JE, PRS and CVB conceptualized, wrote, revised and ap‐

profiling in understanding a non‐dopaminergic and non‐CNS organ

proved the final version of the manuscript. JYL, JPT and CVB con‐

contribution to PD pathology. Equally important is the recognition

ducted the experiments, collected and analysed the data. JYL, JPT,

that CBP may contribute to the by‐stander effects of cell therapy

JE, PRS and CVB interpreted the data.

in PD by targeting the gut microbiome. Along this line of investi‐
gation, such by‐stander effects were previously examined in PD
rats 35,42 and primates. 36 The extent to which the stem cell‐se‐
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creted therapeutic substances reach the striatum and substantia

All data reported herein are stored in the Department of

nigra following intravascular transplantation will be of valuable
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translational and optimization guidance in advancing CBP and stem

Morsani College of Medicine, and will be available upon request with

cell‐based therapy,

36,44

especially for targeting the gut microbiome

appropriate end‐user agreement.

in PD treatment.
In conclusion our study results show that multiple administrations
of CBP in a MPTP gut‐induced rat model of PD effectively reduced
motor and non‐motor dysfunction, which were accompanied by sup‐
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pression of the pro‐inflammatory cytokine production in both the
brain and gut. A decrease in prevalence of several harmful microbiotic
species found in the gut of these animals was also observed. While ad‐
ditional motor and neurological testing, such as paw grasp testing and
forelimb akinesia, were primarily used in this study to validate the gen‐
eration of PD‐like motor dysfunction in an intraperitoneally injected
MPTP rat model, some trends of amelioration of motor deficits result‐
ing from multiple injections of CBP were observed (data not shown).
Interestingly, the therapeutic effects of iv CBP administration appear
not limited to the brain function, but attenuate non‐motor symptoms
(gut motility) as well. These findings indicate that additional studies
investigating both a longer therapeutic time period and potentially
larger doses of CBP should be investigated as these modifications may
improve therapeutic efficacy. Additionally, that CBP robustly restored
the non‐motor gut functions in PD suggests that monitoring of specific
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